{
 "version": "https://jsonfeed.org/version/1.1",
 "title": "Tirzepatide Provider Comparison",
 "home_page_url": "https://tirzepatideprovidercomparison.com",
 "feed_url": "https://tirzepatideprovidercomparison.com/feed.json",
 "description": "Independent evidence, pricing and provider research on tirzepatide and GLP-1 care.",
 "language": "en-US",
 "authors": [
  {
   "name": "S.J Partners LLC",
   "url": "https://tirzepatideprovidercomparison.com"
  }
 ],
 "items": [
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-503b-bulks-exclusion-proposal/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-503b-bulks-exclusion-proposal/",
   "title": "FDA Proposes Permanent Exclusion of Semaglutide, Tirzepatide and Liraglutide From the 503B Bulks List",
   "summary": "The agency found no clinical need for outsourcing facilities to compound these drugs from bulk substances. If finalised, it closes the last pathway for compounding at scale.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-comment-period-extension-503b/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-comment-period-extension-503b/",
   "title": "Comment Period on the GLP-1 Bulks Proposal Extended to 30 July",
   "summary": "FDA granted a 60-day extension after a request for more time. The window now closes days from publication, with no final determination in sight.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-25-warning-letters-june-2026/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-25-warning-letters-june-2026/",
   "title": "FDA Sends 25 More Warning Letters Over Compounded GLP-1 Marketing Claims",
   "summary": "The June letters continue a pattern running back to September 2025, and the target is consistent: what providers say their product is.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/foundayo-orforglipron-fda-approval/",
   "url": "https://tirzepatideprovidercomparison.com/news/foundayo-orforglipron-fda-approval/",
   "title": "FDA Approves Foundayo (Orforglipron), the First Small-Molecule Oral GLP-1 for Weight Loss",
   "summary": "A once-daily pill with no food or water restrictions, available from $149 a month self-pay \u2014 and the lowest mean weight reduction of any approved option.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/wegovy-pill-oral-semaglutide-approval/",
   "url": "https://tirzepatideprovidercomparison.com/news/wegovy-pill-oral-semaglutide-approval/",
   "title": "FDA Approves the Wegovy Pill: Oral Semaglutide 25 mg for Weight Management",
   "summary": "The first oral GLP-1 approved for weight loss, with cardiovascular risk reduction on the label and results close to the injectable.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/step-up-semaglutide-7-2mg/",
   "url": "https://tirzepatideprovidercomparison.com/news/step-up-semaglutide-7-2mg/",
   "title": "STEP UP: Semaglutide 7.2 mg Reports 20.7% Weight Loss, Narrowing the Gap With Tirzepatide",
   "summary": "A threefold increase on the approved dose brings semaglutide close to tirzepatide's SURMOUNT-1 figure \u2014 if tolerability holds.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/medicare-glp1-bridge-launches/",
   "url": "https://tirzepatideprovidercomparison.com/news/medicare-glp1-bridge-launches/",
   "title": "Medicare GLP-1 Bridge Opens: $50 a Month for Eligible Part D Enrollees",
   "summary": "For the first time Medicare covers GLP-1s for weight loss \u2014 through a demonstration programme that expires at the end of 2027 with no confirmed successor.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/balance-model-part-d-delayed/",
   "url": "https://tirzepatideprovidercomparison.com/news/balance-model-part-d-delayed/",
   "title": "CMS Delays the BALANCE Model Indefinitely and Extends the GLP-1 Bridge Instead",
   "summary": "The programme meant to succeed the Bridge has been postponed without a new date, leaving temporary access with nothing confirmed behind it.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/trumprx-launch-direct-pricing/",
   "url": "https://tirzepatideprovidercomparison.com/news/trumprx-launch-direct-pricing/",
   "title": "TrumpRx Launches Direct GLP-1 Pricing, Undercutting List Prices by Up to Nine Times",
   "summary": "A direct-to-consumer channel advertising semaglutide tablets from $149 and tirzepatide injections from $299, against list prices above $1,000.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/novocare-wegovy-price-cut/",
   "url": "https://tirzepatideprovidercomparison.com/news/novocare-wegovy-price-cut/",
   "title": "NovoCare Cuts Wegovy Self-Pay Pricing to $349 From $499",
   "summary": "A 30% reduction on the manufacturer's direct channel, and part of a broader repricing that has reshaped the affordability argument.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/soul-trial-oral-semaglutide-cardiovascular/",
   "url": "https://tirzepatideprovidercomparison.com/news/soul-trial-oral-semaglutide-cardiovascular/",
   "title": "SOUL: Oral Semaglutide Cuts Major Cardiovascular Events by 14% in High-Risk Type 2 Diabetes",
   "summary": "A 9,647-patient outcomes trial reporting a 14% reduction in MACE and 22% in heart failure events \u2014 a hard-endpoint result in a field dominated by surrogate measures.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/evoke-alzheimers-null-result/",
   "url": "https://tirzepatideprovidercomparison.com/news/evoke-alzheimers-null-result/",
   "title": "EVOKE and EVOKE+: Oral Semaglutide Made No Difference to Alzheimer's Progression",
   "summary": "A 3,808-patient, two-year programme returned a null result \u2014 and null results in this field deserve more coverage than they get.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/reimagine-2-cagrisema-diabetes/",
   "url": "https://tirzepatideprovidercomparison.com/news/reimagine-2-cagrisema-diabetes/",
   "title": "REIMAGINE 2: CagriSema Beats Semaglutide on HbA1c by 1.91 Points With 14.2% Weight Loss",
   "summary": "The furthest-advanced next-generation combination reports in type 2 diabetes, ahead of an FDA response expected during 2026.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/synchronize-1-visceral-liver-fat/",
   "url": "https://tirzepatideprovidercomparison.com/news/synchronize-1-visceral-liver-fat/",
   "title": "SYNCHRONIZE-1: 16.6% Weight Loss With 34% Less Visceral Fat and 63% Less Liver Fat",
   "summary": "A 76-week phase 3 readout measuring where fat is lost, not only how much \u2014 which is the more clinically informative question.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/structure-therapeutics-oral-access-ii/",
   "url": "https://tirzepatideprovidercomparison.com/news/structure-therapeutics-oral-access-ii/",
   "title": "ACCESS II: A Second Oral Small-Molecule GLP-1 Posts 16.3% Placebo-Adjusted Weight Loss",
   "summary": "Structure Therapeutics reports phase 2 results with no fasting window required \u2014 a direct challenge to oral semaglutide's administration burden.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-peptide-advisory-committee-july-2026/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-peptide-advisory-committee-july-2026/",
   "title": "FDA Advisory Committee Reviews BPC-157, TB-500 and Five Other Peptides This Week",
   "summary": "Briefing documents posted in June recommended against adding any of the seven to the 503A compounding list. The committee met on 23 and 24 July.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/generic-tirzepatide-anda-filings/",
   "url": "https://tirzepatideprovidercomparison.com/news/generic-tirzepatide-anda-filings/",
   "title": "Sandoz and Amneal File for Generic Tirzepatide \u2014 But Lilly's Patents Run to 2036",
   "summary": "An ANDA filing is the start of a legal process, not an imminent launch. Anything sold as generic tirzepatide today is not one.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-february-2026-api-restriction/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-february-2026-api-restriction/",
   "title": "FDA Signals It Will Restrict GLP-1 Active Ingredients Used in Non-Approved Compounded Products",
   "summary": "The February announcement was the turn from warning letters to structural action, and the bulks proposal followed twelve weeks later.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/tirzepatide-shortage-timeline-litigation/",
   "url": "https://tirzepatideprovidercomparison.com/news/tirzepatide-shortage-timeline-litigation/",
   "title": "The Tirzepatide Shortage Delisting Was Not One Date \u2014 It Was a Year of Litigation",
   "summary": "Widely reported as 'October 2024', the delisting was determined, remanded, contested and re-affirmed across five months. We had it wrong too.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/compounded-b12-chemical-bonding-study/",
   "url": "https://tirzepatideprovidercomparison.com/news/compounded-b12-chemical-bonding-study/",
   "title": "A 2026 Study Finds Tirzepatide and B12 Can Chemically Bond \u2014 Forming a Molecule Not in the Approved Drug",
   "summary": "Additives used to differentiate compounded products from their approved counterparts are largely untested, and at least one interacts.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/surmount-5-published-nejm/",
   "url": "https://tirzepatideprovidercomparison.com/news/surmount-5-published-nejm/",
   "title": "SURMOUNT-5 Published: Tirzepatide 20.2% Against Semaglutide 13.7% in the First Head-to-Head",
   "summary": "751 adults, 72 weeks, maximum tolerated doses of each \u2014 the only trial that has compared these two drugs directly for weight management.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/summit-hfpef-results/",
   "url": "https://tirzepatideprovidercomparison.com/news/summit-hfpef-results/",
   "title": "SUMMIT: Tirzepatide Cuts Worsening Heart-Failure Events by 38% in Obesity-Related HFpEF",
   "summary": "A 731-patient phase 3 trial in a specific cardiac phenotype, with imaging substudies supporting a mechanical explanation.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/surmount-1-three-year-diabetes-prevention/",
   "url": "https://tirzepatideprovidercomparison.com/news/surmount-1-three-year-diabetes-prevention/",
   "title": "Three Years of Tirzepatide Markedly Reduced Progression to Type 2 Diabetes in Prediabetes",
   "summary": "The longest published follow-up in this field: 1,032 participants, 176 weeks of treatment, and a hard clinical endpoint rather than a surrogate.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/zepbound-osa-indication/",
   "url": "https://tirzepatideprovidercomparison.com/news/zepbound-osa-indication/",
   "title": "Zepbound Now Carries an Obstructive Sleep Apnoea Indication Alongside Weight Management",
   "summary": "The first GLP-1 approved for a sleep disorder, following the SURMOUNT-OSA programme \u2014 and a coverage implication for patients whose plans exclude weight management.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/gallup-glp1-use-obesity-decline/",
   "url": "https://tirzepatideprovidercomparison.com/news/gallup-glp1-use-obesity-decline/",
   "title": "GLP-1 Use Reaches 11% of US Adults as the Obesity Rate Falls to 36.4%",
   "summary": "Current use has nearly quadrupled in two years. Over the same period national obesity prevalence declined from its 2022 peak.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/ada-2026-bimagrumab-lean-mass/",
   "url": "https://tirzepatideprovidercomparison.com/news/ada-2026-bimagrumab-lean-mass/",
   "title": "ADA 2026: Adding a Myostatin Inhibitor Cut the Lean-Mass Share of Weight Loss From 21% to 7%",
   "summary": "The first strong signal that the composition of GLP-1 weight loss is pharmacologically modifiable \u2014 with a large gap still open on function.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/ada-2026-osteoarthritis-outcomes/",
   "url": "https://tirzepatideprovidercomparison.com/news/ada-2026-osteoarthritis-outcomes/",
   "title": "ADA 2026: Semaglutide Improved Knee Osteoarthritis Pain \u2014 and Tirzepatide's Extra Weight Loss Did Not Add More",
   "summary": "Meaningful WOMAC reduction and less analgesic use, with an asymmetry that raises a question about mechanism.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/wegovy-pill-three-million-prescriptions/",
   "url": "https://tirzepatideprovidercomparison.com/news/wegovy-pill-three-million-prescriptions/",
   "title": "The Wegovy Pill Passed Three Million Prescriptions in Just Over Five Months",
   "summary": "An uptake rate suggesting the oral route addressed a real barrier rather than offering a marginal alternative.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/semaglutide-shortage-resolved-enforcement/",
   "url": "https://tirzepatideprovidercomparison.com/news/semaglutide-shortage-resolved-enforcement/",
   "title": "Semaglutide Came Off the Shortage List in February 2025 \u2014 With a May Deadline for Outsourcing Facilities",
   "summary": "The delisting closed the pathway that had permitted compounding at scale, on a defined wind-down timetable.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/hims-compounded-wegovy-pill-withdrawal/",
   "url": "https://tirzepatideprovidercomparison.com/news/hims-compounded-wegovy-pill-withdrawal/",
   "title": "A Major Telehealth Platform Withdrew a Compounded Copy of the Wegovy Pill Under Legal Threat",
   "summary": "The episode is widely cited as the point at which FDA enforcement shifted focus from compounders to the platforms marketing them.",
   "date_published": "2026-07-24T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/fda-panel-votes-peptides-503a-july-2026/",
   "url": "https://tirzepatideprovidercomparison.com/news/fda-panel-votes-peptides-503a-july-2026/",
   "title": "FDA Panel Recommends Six of Seven Peptides for Compounding, Overriding Its Own Scientists",
   "summary": "Across 23-24 July the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list against unanimous staff advice, rejecting only emideltide. The votes are non-binding, each is indication-specific, and nothing is lawful yet.",
   "date_published": "2026-07-25T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/nad-willow-compounded-semaglutide-claims/",
   "url": "https://tirzepatideprovidercomparison.com/news/nad-willow-compounded-semaglutide-claims/",
   "title": "Telehealth company drops compounded semaglutide ad claims after Novo challenge",
   "summary": "BBB National Programs' National Advertising Division announced on 24 July that Willow Health Services has permanently discontinued the claims. The matter had been reopened following a December 2025 decision and a referral to the FTC and state attorneys general.",
   "date_published": "2026-07-28T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/total-mens-primary-care-csa-settlement/",
   "url": "https://tirzepatideprovidercomparison.com/news/total-mens-primary-care-csa-settlement/",
   "title": "Telehealth group agrees consent judgment of up to $600,000 over controlled substance allegations",
   "summary": "The US Attorney for the Western District of Texas announced that Total MD Physicians Group, trading as Total Men's Primary Care, and Dr Mason Jones agreed to pay civil penalties to resolve alleged Controlled Substances Act violations. The claims are allegations only and there has been no determination of liability.",
   "date_published": "2026-07-28T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/idaho-physician-sentenced-telemedicine-orders/",
   "url": "https://tirzepatideprovidercomparison.com/news/idaho-physician-sentenced-telemedicine-orders/",
   "title": "Physician sentenced to 40 months for signing telemedicine orders for patients he never examined",
   "summary": "A federal judge sentenced Dr David Antonio Becerril of Coeur d'Alene, Idaho, and ordered more than $1.25 million in restitution. Prosecutors said he spent about 26 seconds on each order.",
   "date_published": "2026-07-28T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/cms-2027-remote-monitoring-outsourcing/",
   "url": "https://tirzepatideprovidercomparison.com/news/cms-2027-remote-monitoring-outsourcing/",
   "title": "CMS proposes barring Medicare payment for outsourced remote monitoring",
   "summary": "The proposed CY2027 Physician Fee Schedule would require remote physiologic and therapeutic monitoring to be furnished by a practice's own employed clinical staff. It is not final and comments run to 14 September 2026.",
   "date_published": "2026-07-28T00:00:00Z"
  },
  {
   "id": "https://tirzepatideprovidercomparison.com/news/nexlife-names-fulfilment-pharmacies/",
   "url": "https://tirzepatideprovidercomparison.com/news/nexlife-names-fulfilment-pharmacies/",
   "title": "First provider in our dataset names its fulfilment pharmacies",
   "summary": "NexLife's plan pages name five partners and disclose both 503A and 503B pathways. It is the first provider of 29 to answer the pharmacy question, and the first to have answered all four of our disclosure questions.",
   "date_published": "2026-07-28T00:00:00Z"
  }
 ]
}